Patient enrollment and dosing completed for phase I clinical trial of AK0610, a preventive antibody against RSV infection

Phase III clinical trial results of ziresovir for the treatment of RSV infection published in the New England Journal of Medicine

Patient enrollment completed for phase II clinical trial of AK3280, a next-generation drug for IPF treatment

ArkBio is listed in the "2023 Top 50 Most Investable Healthcare Companies"

Renewed co-development collaboration with Calibr on the development of AK0705

Initiated the registration bridging clinical trial of AK0901

The IND application of AK0610 approved

 Initiated AK3280's phase 2 study in China

 Initiated AK3287's phase 1/2 study

 Ziresovir's phase 3 study completed, primary endpoint & key secondary endpoints met

 Completed series D round of fundraising

 AK0529's NDA has been accepted and granted Priority Review by NMPA

 Completed series C round of fundraising

 Initiated ziresovir's phase 1 study in the US

 In-licensed FDA-approved ADHD treatment AZSTARYS from Commave

 First-time presentation at J.P. Morgan Healthcare Conference

 Initiated ziresovir's phase 3 study

 Out-licensed AK0706's China rights to Amoytop

 Ziresovir received breakthrough designation by NMPA

 Awarded gold medal in innovation competition by National Health Commission of China for the development of ziresovir

Initiated AK3280 phase 1b study in Sweden

 Completed series B round of fundraising

 In-licensed AK3280 global rights from Genentech/Intermune/Roche

 Completed series A+ round of fundraising

 Completed ziresovir's Chinese phase 1 study and first Chinese adult dosing

 Started collaboration with Calibr on the development of AK0705

 Established Suzhou R&D Center

Completed series A round of fundraising

 Ark Biopharmaceutical founded

 In-licensed ziresovir global rights from Roche

 Initiated ziresovir's phase 1 study in Australia and completed FIH dosing

 Completed angel round of fundraising

 Ark Biosciences Inc. founded